2023-505542-26-00CompletedPhase 1
A first-in-human, randomized, participant and investigator blinded, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of HJB647 in healthy participants and otherwise healthy participants with elevated blood pressure, with an open-label CYP3A inhibitor drug-drug interaction part
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Nov 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 106 (actual)
- First submitted
- 25 Sept 2023
- Start date
- 30 Nov 2023
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Heart failure
- EU CT number
- 2023-505542-26-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 106
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.